GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (STU:25I) » Definitions » Construction In Progress

ImmuPharma (STU:25I) Construction In Progress : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2012. Start your Free Trial

What is ImmuPharma Construction In Progress?


ImmuPharma Construction In Progress Historical Data

The historical data trend for ImmuPharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Construction In Progress Chart

ImmuPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ImmuPharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ImmuPharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


ImmuPharma (STU:25I) Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (STU:25I) Headlines

No Headlines